Evidence for the role of gonadotropin hormones in the development of Alzheimer disease

Cellular and Molecular Life Sciences

Volumn 62, Issue 3, 2005, Pages 293-298

  Casadesus, G ^a   Atwood, C S ^b   Zhu, X ^a   Hartzler, A W ^a   Webber, K M ^a   Perry, G ^a   Bowen, R L ^c   Smith, M A ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c Voyager Pharmaceutical Corporation   (United States)

Author keywords

Hormone replacement therapy (HRT); Leuprolide acetate; Luteinizing hormone (LH)

Indexed keywords

ACTIVIN; AMYLOID BETA PROTEIN; ESTRADIOL; ESTROGEN; FOLLISTATIN; FOLLITROPIN; GONADORELIN AGONIST; GONADOTROPIN; INHIBIN; LEUPRORELIN; LUTEINIZING HORMONE; PROGESTERONE; SEX HORMONE; TESTOSTERONE;

ALZHEIMER DISEASE; ANDROPAUSE; CELL CULTURE; CELL CYCLE; CLINICAL TRIAL; COGNITION; DEMENTIA; DISEASE COURSE; DOWN SYNDROME; ESTROGEN DEFICIENCY; FEEDBACK SYSTEM; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LUTEINIZING HORMONE BLOOD LEVEL; MENOPAUSE; NONHUMAN; ONSET AGE; OOCYTE DEVELOPMENT; REVIEW; SEX ROLE; SPERMATOGENESIS; AGING; FEMALE; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALIA;

AGING; ALZHEIMER DISEASE; FEMALE; GONADOTROPINS; HUMANS; LUTEINIZING HORMONE; MALE;

EID: 14844331838     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-4384-0     Document Type: Review

References (71)

1. Smith M. A. (1998) Alzheimer disease. Int. Rev. Neurobiol. 42: 1-54
2. Selkoe D. J. (2003) Aging, amyloid and Alzheimer's disease: a perspective in honor of Carl Cotman. Neurochem. Res. 28: 1705-1713
3. Selkoe D. J. (1997) Alzheimer's disease: genotypes, phenotypes and treatments. Science 275: 630-631
4. Savonenko A. V., Xu G. M., Price D. L., Borchelt D. R. and Markowska A. L. (2003) Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE. Neurobiol. Dis. 12: 194-211
5. Takeuchi A., Irizarry M. C., Duff K., Saido T. C., Hsiao Ashe K., Hasegawa M. et al. (2000) Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol. 157: 331-339
6. Irizarry M. C., Soriano F., McNamara M., Page K. J., Schenk D., Games D. et al. (1997) Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17: 7053-7059
7. Perry G., Nunomura A., Raina A. K. and Smith M. A. (2000) Amyloid-beta junkies. Lancet 355: 757
8. Obrenovich M. E., Joseph, J.A., Atwood, C.S., Perry, G., Smith, M. A. (2003) Alzheimer Disease - A New Beginning, or a Final Exit? Landes Bioscience, TX
9. Rottkamp C. A., Atwood C. S., Joseph J. A., Nunomura A., Perry G. and Smith M. A. (2002) The state versus amyloid-beta: the trial of the most wanted criminal in Alzheimer disease. Peptides 23: 1333-1341
10. Trojanowski J. Q., Clark C. M., Arai H. and Lee V. M. (1999) Elevated levels of tau in cerebrospinal fluid: implications for the antemortem diagnosis of alzheimer's disease. J. Alzheimers Dis. 1: 297-305
11. Avila J. (2000) Tau aggregation into fibrillar polymers: taupathies. FEBS Lett. 476: 89-92
12. Zhu X., Lee H. G., Raina A. K., Perry G. and Smith M. A. (2002) The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 11: 270-281
13. Perry G., Castellani R. J., Hirai K. and Smith M. A. (1998) Reactive oxygen species mediate cellular damage in Alzheimer disease. J. Alzheimers Dis. 1: 45-55
14. Perry G., Sayre L. M., Atwood C. S., Castellani R. J., Cash A. D., Rottkamp C. A. et al. (2002) The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs 16: 339-352
15. Attwood C. S., Huang X., Moir R. D., Smith M. A., Tanzi R. E., Roher A. E. et al. (2001) Neuroinflammatory Responses in the Alzheimer's Disease Brain Promote the Oxidative Post-Translational Modification of Amyloid Deposits, John Wiley, UK
16. Shumaker S. A., Legault C., Rapp S. R., Thai L., Wallace R. B., Ockene J. K. et al. (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651-2662
17. Mulnard R. A. (2000) Estrogen as a treatment for Alzheimer disease. JAMA 284: 307-308
18. Mulnard R. A., Cotman C. W., Kawas C., van Dyck C. H., Sano M., Doody R. et al. (2000) Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 283: 1007-1015
19. Bowen R. L., Verdile G., Liu T., Parlow A. F., Perry G., Smith M. A. et al. (2004) Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J. Biol. Chem. 279: 20539-20545
20. Jaffe A. B., Toran-Allerand C. D., Greengard P. and Gandy S. E. (1994) Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J. Biol. Chem. 269: 13065-13068
21. Manthey D., Heck S., Engert S. and Behl C. (2001) Estrogen induces a rapid secretion of amyloid beta precursor protein via the mitogen-activated protein kinase pathway. Eur. J. Biochem. 268: 4285-4291
22. Chang D., Kwan J. and Timiras P. S. (1997) Estrogens influence growth, maturation and amyloid beta-peptide production in neuroblastoma cells and in a beta-APP transfected kidney 293 cell line. Adv. Exp. Med. Biol. 429: 261-271
23. Gouras G. K., Xu H., Gross R. S., Greenfield J. P., Hai B., Wang R. et al. (2000) Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. Proc. Natl. Acad. Sci. USA 97: 1202-1205
24. Zheng H., Xu H., Uljon S. N., Gross R., Hardy K., Gaynor J. et al. (2002) Modulation of A(beta) peptides by estrogen in mouse models. J. Neurochem. 80: 191-196
25. Petanceska S. S., Nagy V., Frail D. and Gandy S. (2000) Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Exp. Gerontol. 35: 1317-1325
26. Levin-Allerhand J. A. and Smith J. D. (2002) Ovariectomy of young mutant amyloid precursor protein transgenic mice leads to increased mortality. J. Mol. Neurosci. 19: 163-166
27. Stam F. C., Wigboldus J. M. and Smeulders A. W. (1986) Age incidence of senile brain amyloidosis. Pathol. Res. Pract. 181: 558-562
28. Genazzani A. R., Gastaldi M., Bidzinska B., Mercuri N., Genazzani A. D., Nappi R. E. et al. (1992) The brain as a target organ of gonadal steroids. Psychoneuroendocrinology 17: 385-390
29. Couzinet B. and Schaison G. (1993) The control of gonadotrophin secretion by ovarian steroids. Hum. Reprod. 8 Suppl. 2: 97-101
30. Chakravarti S., Collins W. P., Forecast J. D., Newton J. R., Oram D. H. and Studd J. W. (1976) Hormonal profiles after the menopause. Br. Med. J. 2: 784-787
31. Neaves W. B., Johnson L., Porter J. C., Parker C. R. Jr and Petty C. S. (1984) Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J. Clin. Endocrinol. Metab. 59: 756-763
32. Burger H. G. (1996) The endocrinology of the menopause. Maturitas 23: 129-136
33. Henderson V. W. (2004) Hormone therapy and Alzheimer's disease: benefit or harm? Expert. Opin. Pharmacother. 5: 389-406
34. Henderson V. W., Guthrie J. R., Dudley E. C., Burger H. G. and Dennerstein E. (2003) Estrogen exposures and memory at midlife: a population-based study of women. Neurology 60: 1369-1371
35. Bowen R. L., Isley J. P. and Atkinson R. L. (2000) An association of elevated serum gonadotropin concentrations and Alzheimer disease? J. Neuroendocrinol. 12: 351-354
36. Short R. A., Bowen R. E., O'Brien P. C. and Graff-Radford N. R. (2001) Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin. Proc. 76: 906-909
37. Breitner J. C., Silverman J. M., Mohs R. C. and Davis K. L. (1988) Familial aggregation in Alzheimer's disease: comparison of risk among relatives of early-and late-onset cases, and among male and female relatives in successive generations. Neurology 38: 207-212
38. Jorm A. F. and Jolley D. (1998) The incidence of dementia: a meta-analysis. Neurology 51: 728-733
39. McGonigal G., Thomas B., McQuade C., Starr J. M., MacLennan W. J. and Whalley L. J. (1993) Epidemiology of Alzheimer's presenile dementia in Scotland, 1974-88. BMJ. 306: 680-683
40. Rocca W. A., Hofman A., Brayne C., Breteler M. M., Clarke M., Copeland J. R. et al. (1991) Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann. Neurol. 30: 381-390
41. Jorm A. F., Korten A. E. and Henderson A. S. (1987) The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr. Scand. 76: 465-479
42. Schupf N., Kapell D., Nightingale B., Rodriguez A., Tycko B. and Mayeux R. (1998) Earlier onset of Alzheimer's disease in men with Down syndrome. Neurology 50: 991-995
43. Webber K. B. R., Casadesus G., Perry G., Atwood C. S. and Smith M. A. (2004) Gonadotropins and Alzheimer's disease: the link between estrogen replacement therapy and neuroprotection. Acta Neurobiol. Exp. 64: 113-118
44. Lukacs H., Hiatt E. S., Lei Z. M. and Rao C. V. (1995) Peripheral and intracerebroventricular administration of human chorionic gonadotropin alters several hippocampus-associated behaviors in cycling female rats. Horm. Behav. 29: 42-58
45. Bowen R. L., Smith M. A., Harris P. L., Kubat Z., Martins R. N., Castellani R. J. et al. (2002) Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J. Neurosci. Res. 70: 514-518
46. Lei Z. M., Rao C. V., Kornyei J. L., Licht P. and Hiatt E. S. (1993) Novel expression of human chorionic gonadotropin/luteinizing hormone receptor gene in brain. Endocrinology 132: 2262-2270
47. Al-Hader A. A., Lei Z. M. and Rao C. V. (1997) Novel expression of functional luteinizing hormone/chorionic gonadotropin receptors in cultured glial cells from neonatal rat brains. Biol. Reprod. 56: 501-507
48. Al-Hader A. A., Lei Z. M. and Rao C. V. (1997) Neurons from fetal rat brains contain functional luteinizing hormone/chorionic gonadotropin receptors. Biol. Reprod. 56: 1071-1076
49. Raina A. K., Zhu X., Rottkamp C. A., Monteiro M., Takeda A. and Smith M. A. (2000) Cyclin' toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J. Neurosci. Res. 61: 128-133
50. Ogawa O., Lee H. G., Zhu X., Raina A., Harris P. L., Castellani R. J. et al. (2003) Increased p27, an essential component of cell cycle control, in Alzheimer's disease. Aging Cell 2: 105-110
51. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E. K. et al. (2001) Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp.Neurol. 60: 759-767
52. Rimon E., Sasson R., Dantes A., Land-Bracha A. and Amsterdam A. (2004) Gonadotropin-induced gene regulation in human granulosa cells obtained from IVF patients: modulation of genes coding for growth factors and their receptors and genes involved in cancer and other diseases. Int. J. Oncol. 24: 1325-1338
53. Xu H., Gouras G. K., Greenfield J. P., Vincent B., Naslund J., Mazzarelli L. et al. (1998) Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat. Med. 4: 447-451
54. Casadesus G., Ogawa, O., Bowen, R.L., Atwood, C.S., Perry, G., Smith, M.A. (2003) Modulation of hippocampal plasticity and cognition in the swAPP transgenic mouse by the gonadotropin-releasing hormone agonist leuprolide acetate: involvement of luteinizing hormone in the pathogenesis and treatment of AD. Soc. Neuroci Abs., Program No. 945, 8, 2003
55. Smith M. A., Perry G., Atwood C. S. and Bowen R. L. (2003) Estrogen replacement and risk of Alzheimer disease. JAMA 289: 1100; author reply 1101-1102
56. McShea A., Harris P. L., Webster K. R., Wahl A. F. and Smith M. A. (1997) Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am. J. Pathol. 150: 1933-1939
57. Hirai K., Aliev G., Nunomura A., Fujioka H., Russell R. L., Atwood C. S. et al. (2001) Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 21: 3017-3023
58. Zhu X., Raina A. K., Boux H., Simmons Z. L., Takeda A. and Smith M. A. (2000) Activation of oncogenic pathways in degenerating neurons in Alzheimer disease. Int. J. Dev. Neurosci. 18: 433-437
59. Bowser R. and Smith M. A. (2002) Cell cycle proteins in Alzheimer's disease: plenty of wheels but no cycle. J. Alzheimers. Dis. 4: 249-254
60. Sriraman V., Rao V. S., Rajesh N., Vasan S. S. and Rao A. J. (2001) A preliminary study on the possible role for luteinizing hormone in androgen independent growth of prostate. Reprod. Biomed. Online 3: 6-13
61. Harris D., Bonfil D., Chuderland D., Kraus S., Seger R. and Naor Z. (2002) Activation of MAPK cascades by GnRH: ERK and Jun N-terminal kinase are involved in basal and GnRH-stimulated activity of the glycoprotein hormone LHbeta-subunit promoter. Endocrinology 143: 1018-1025
62. Keeney D. S., Sprando R. L., Robaire B., Zirkin B. R. and Ewing L. L. (1990) Reversal of long-term LH deprivation on testosterone secretion and Leydig cell volume, number and proliferation in adult rats. J. Endocrinol. 127: 47-58
63. Athreya B. H., Pletcher J., Zulian F., Weiner D. B. and Williams W. V. (1993) Subset-specific effects of sex hormones and pituitary gonadotropins on human lymphocyte proliferation in vitro. Clin. Immunol. Immunopathol. 66: 201-211
64. Sabharwal P., Varma S. and Malarkey W. B. (1992) Human thymocytes secrete luteinizing hormone: an autocrine regulator of T-cell proliferation. Biochem. Biophys. Res. Commun. 187: 1187-1192
65. Costa O., Bouthet C., Sauvage P., Michel J. P. and Deschaux P. (1990) Age-dependent LH and FSH effect on the proliferation of women's peripheral blood lymphocytes in vitro. Int. J. Immunopharmacol. 12: 821-829
66. Cameron M. R., Foster J. S., Bukovsky A. and Wimalasena J. (1996) Activation of mitogen-activated protein kinases by gonadotropins and cyclic adenosine 5′-monophosphates in porcine granulosa cells. Biol. Reprod. 55: 111-119
67. Carvalho C. R., Carvalheira J. B., Lima M. H., Zimmerman S. F., Caperuto L. C., Amanso A. et al. (2003) Novel signal transduction pathway for luteinizing hormone and its interaction with insulin: activation of Janus kinase/signal transducer and activator of transcription and phosphoinositol 3-kinase/Akt pathways. Endocrinology 144: 638-647
68. Rubinfeld H. and Seger R. (2004) The ERK cascade as a prototype of MAPK signaling pathways. Methods Mol. Biol. 250: 1-28
69. Zhu X., Castellani R. J., Takeda A., Nunomura A., Atwood C. S., Perry G. et al. (2001) Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech. Ageing. Dev. 123: 39-46
70. Zhu X., Raina A. K., Perry G. and Smith M. A. (2004) Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 3: 219-226
71. Perry G., Roder H., Nunomura A., Takeda A., Friedlich A. L., Zhu X. et al. (1999) Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 10: 2411-2415